Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

New York University Langone Medical Center, New York

Walter Reed National Military Medical Center, Bethesda

Moffitt Cancer Center, Tampa

Tennessee Oncology, PLLC, Nashville

Vanderbilt University, Nashville

University of Wisconsin Carbone Cancer Ctr, Madison

Washington University School of Medicine, St Louis

University of Texas MD Anderson Cancer Center, Houston

University of Southern California Norris Comprehensive Cancer Center, Los Angeles

City of Hope National Med Ctr, Duarte

UCSD Moores Cancer Center, La Jolla

Stanford University, Stanford

Providence Portland Medical Center, Portland

Dana Farber Cancer Institute, Boston